Key result
Beta-blockers linked to ~28% lower all-cause mortality in systolic HF patients excluded from MERIT-HF.
Why the study?
Beta-blockers improve prognosis in chronic systolic heart failure patients, but many clinical patients do not meet trial inclusion criteria such as those of MERIT-HF.
Does beta-blocker treatment reduce all-cause mortality in patients with chronic systolic heart failure who meet exclusion criteria for the MERIT-HF trial?
Cohort (n=675)
Does beta-blocker treatment reduce all-cause mortality in patients with chronic systolic heart failure who meet exclusion criteria for the MERIT-HF trial?
Beta-blocker therapy is associated with significantly reduced long-term mortality in patients with chronic systolic heart failure, even among those with comorbidities or characteristics that would have excluded them from landmark randomized trials like MERIT-HF.
Answers are grounded in this paper and cite their sources.
Beta-blocker use was associated with lower mortality in non-trial HF patients; leaves open extension of RCT benefits to broader populations.
AIMS: Improved prognosis of patients with chronic systolic heart failure by treatment with beta-blockers has been shown in several randomized controlled multicentre trials. However, in clinical practice only a part of heart failure patients meet the inclusion criteria of these trials. The present study evaluates whether reduction of mortality by beta-blockers also can be achieved in patients presenting one or more exclusion criteria of the MERIT-HF trial. METHODS AND RESULTS: From the Ludwigshafen Heart Failure Registry 675 patients with chronic systolic heart failure consecutively enrolled between January 1995 and June 2004 were divided in two groups either meeting the inclusion criteria of the MERIT-HF trial ('trial patients': n = 278, 60% treated with beta-blockers) or not ('non-trial patients': n = 397; 51% treated with beta-blockers). The distribution of the MERIT-HF exclusion criteria in the group of 'non-trial patients' was as follows: acute myocardial infarction 9.6%; systolic blood pressure <100 mmHg 7.5%; chronic obstructive lung disease 33.2%; other serious diseases potentially limiting prognosis 16.9%; acutely performed or planned ICD, bypass surgery, PCI, heart transplantation: 17.1, 15.9, 7.8, and 4.8%, respectively. Median follow-up was 31.3 months (upper/lower quartile 16.3/50.0 months). All-cause mortality was significantly reduced by beta-blocker treatment not only in 'trial patients' (adjusted hazard ratio 0.57, 95% CI 0.38-0.86) but also in 'non-trial patients' (adjusted hazard ratio 0.72, 95% CI 0.53-0.97). CONCLUSION: In clinical practice only the smaller part of the population to be treated for chronic systolic heart failure meets the inclusion criteria of the MERIT-HF study. However, beta-blocker treatment is associated with a significantly reduced long-term mortality even in patients meeting one or more exclusion criteria of the MERIT-HF study.
No takes yet. Share an insight, caveat, or question.
Jost et al. (2005) conducted a cohort in chronic systolic heart failure (n=675). Beta-blocker treatment vs. No beta-blocker treatment was evaluated on All-cause mortality (HR 0.72, 95% CI 0.53-0.97). Beta-blocker treatment reduced all-cause mortality in chronic systolic heart failure patients meeting one or more exclusion criteria of the MERIT-HF trial.
Synapse has enriched 10 related papers. Consider them for comparative context: